Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models

Estelle Daudigeos-Dubus; Ludivine Le Dret; Claudia Lanvers-Kaminsky; Olivia Bawa; Paule Opolon; Albane Vievard; Irène Villa; Mélanie Pagès; Jacques Bosq; Gilles Vassal; Dieter Zopf; Birgit Geoerger

doi:10.1371/journal.pone.0142612

Loading metrics

Open Access

Peer-reviewed

Research Article

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models

Estelle Daudigeos-Dubus,

Affiliations Université Paris-Sud 11, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France, CNRS, Vectorology and Anticancer Therapeutics, UMR 8203, Orsay, France, Gustave Roussy, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France
⨯
Ludivine Le Dret,

Affiliations Université Paris-Sud 11, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France, CNRS, Vectorology and Anticancer Therapeutics, UMR 8203, Orsay, France, Gustave Roussy, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France
⨯
Claudia Lanvers-Kaminsky,

Affiliation University Children’s Hospital, Department of Pediatric Hematology and Oncology, Münster, Germany
⨯
Olivia Bawa,

Affiliation PFEP (Plateforme d’évaluation préclinique), Gustave Roussy, Villejuif, France
⨯
Paule Opolon,

Affiliation PFEP (Plateforme d’évaluation préclinique), Gustave Roussy, Villejuif, France
⨯
Albane Vievard,

Affiliation Tribvn, Châtillon, France
⨯
Irène Villa,

Affiliation Pathology Laboratory, Gustave Roussy, Villejuif, France
⨯
Mélanie Pagès,

Affiliations Department of Neuropathology, Sainte-Anne’s Hospital, Paris, France, Paris Descartes University, Paris, France
⨯
Jacques Bosq,

Affiliation Pathology Laboratory, Gustave Roussy, Villejuif, France
⨯
Gilles Vassal,

Affiliations Université Paris-Sud 11, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France, CNRS, Vectorology and Anticancer Therapeutics, UMR 8203, Orsay, France, Gustave Roussy, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France
⨯
Dieter Zopf,

Affiliation Bayer Pharma Aktiengesellschaft, Berlin, Germany
⨯
Birgit Geoerger

* E-mail: birgit.geoerger@gustaveroussy.fr

Affiliations Université Paris-Sud 11, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France, CNRS, Vectorology and Anticancer Therapeutics, UMR 8203, Orsay, France, Gustave Roussy, Vectorology and Anticancer Therapeutics, UMR 8203, Villejuif, France
⨯

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models

Estelle Daudigeos-Dubus,
Ludivine Le Dret,
Claudia Lanvers-Kaminsky,
Olivia Bawa,
Paule Opolon,
Albane Vievard,
Irène Villa,
Mélanie Pagès,
Jacques Bosq,
Gilles Vassal

Published: November 23, 2015
https://doi.org/10.1371/journal.pone.0142612

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Pediatrics
Is the Subject Area "Pediatrics" applicable to this article?

Thanks for your feedback.
Thyroid carcinoma
Is the Subject Area "Thyroid carcinoma" applicable to this article?

Thanks for your feedback.
DNA damage
Is the Subject Area "DNA damage" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.